Rite Aid vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
US pharmacy chain that emerged from Chapter 11 bankruptcy (filed October 2023) following $1.3B+ opioid settlements; competing with CVS and Walgreens with a restructured reduced store network.
About
Rite Aid is a US pharmacy retail chain — historically one of the three largest US drugstore networks alongside CVS and Walgreens — operating neighborhood pharmacies providing prescription medications, immunizations, health screenings, and personal care retail. Founded in 1962 in Scranton, Pennsylvania and headquartered in Camp Hill, Pennsylvania, Rite Aid filed for Chapter 11 bankruptcy protection in October 2023 under the combined pressure of opioid litigation settlements exceeding $1.3 billion, real estate liabilities from 2,200+ store leases, declining pharmacy reimbursement rates from PBMs, and debt from the 2007 acquisition of Eckerd pharmacies. Rite Aid emerged from bankruptcy in 2024 with a restructured balance sheet and reduced store network, closing hundreds of locations while maintaining operations in core markets.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.